Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Artificial intelligence‑driven virtual tumor board enhances precision care in myelodysplastic syndromes (MDS)

David Swoboda, Amy DeZern, James England, Sangeetha Venugopal, Thomas Kehoe, Brandon Aubrey, Marco Gabriele Raddi, Angela Consagra, Jiasheng Wang, Gustavo Rivero, Maximilian Stahl, Amer Zeidan, Torsten Haferlach, Andrew Brunner, Rena Buckstein, Valeria Santini, Matteo Della Porta, Mikkael Sekeres, Aziz Nazha

Blood (2025) 146 (Supplement 1): 7363.

https://doi.org/10.1182/blood-2025-7363

Published: 2025

Journal Articles

Evaluating large language models in real-world hematologic clinical decision-making: Performance, limitations, and clinical implications

Blood (2025) 146 (Supplement 1): 4349.

https://doi.org/10.1182/blood-2025-4349

Published: 2025

Journal Articles

Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study

Alice Mims, Lai Wei, Eric McLaughlin, Jayanshu Jain, Joshua Zeidner, Olatoyosi Odenike, Sangeetha Venugopal, James Blachly, Vu Duong, Anand Patel, Eric Eisenmann, Shelley Orwick, Daelynn Buelow, Gregory Behbehani, Richard Little, Steven Gore, Sharyn Baker

Blood (2025) 146 (Supplement 1): 5206.

https://doi.org/10.1182/blood-2025-5206

Published: 2025

Journal Articles

Preliminary safety and efficacy of the frida study: Iadademstat and gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia

Sangeetha Venugopal, Neil Palmisiano, Guru Subramanian Guru Murthy, Theodore Braun, Alex Ambinder, Jonathan Feld, Sharad Khurana, Stephen Strickland, Rajneesh Nath, Konstantinos Sdrimas, Raquel Ruiz, Beatriz Bruno, Sonia Gutierrez, Douglas Faller, Ana Limon, Amir Fathi

Blood (2025) 146 (Supplement 1): 5197.

https://doi.org/10.1182/blood-2025-5197

Published: 2025

Journal Articles

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Brian Jonas, Sangeetha Venugopal, George Yaghmour, Manu Pandey, Anthony Selwyn Stein, Mikkael Sekeres, Namrata Chandhok, Rasmus Hoeg, Joseph Tuscano, Pamela Becker, Terrence Bradley, Eric Tam, Guido Marcucci, Paul Frankel, Jan Beumer, Steven Gore, Alexey Danilov, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2025-1651

Published: 2025

Journal Articles

Results of the Phase 1B study of pegargiminase (ADI-PEG 20) in combination with AZA-VEN in newly diagnosed high-risk AML patients not candidates for intensive chemotherapy

Justin Watts, Brittany Ragon, Namrata Chandhok, Mikkael Sekeres, Sangeetha Venugopal, Amanda Johnston, Mirla Langlois, Nicole DeFord, John Bomalaski, Naveen Pemmaraju, Nitin Jain, Gautam Borthakur

Blood (2025) 146 (Supplement 1): 1650.

https://doi.org/10.1182/blood-2025-1650

Published: 2025

Journal Articles

Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus

Blood (2025) 146 (Supplement 1): 789.

https://doi.org/10.1182/blood-2025-789

Published: 2025

Journal Articles

Azacitidine and venetoclax for HR-MDS: election results pending

Sangeetha Venugopal, Mikkael A. Sekeres

Blood (2025) 145 (11): 1099–1100.

https://doi.org/10.1182/blood.2024027567

Published: 2025

Journal Articles

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 4597.

https://doi.org/10.1182/blood-2024-206034

Published: 2024

Journal Articles

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

Mikkael A. Sekeres, Hetty E. Carraway, Richard M Stone, Yazan F Madanat, Rami S. Komrokji, Sangeetha Venugopal, Namrata S. Chandhok, Terrence Bradley, Justin Taylor, Anastasia Santiago, Alessia Zoso, Justin M. Watts, Amy E. DeZern

Blood (2024) 144 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2024-203965

Published: 2024

Journal Articles

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 243.

https://doi.org/10.1182/blood-2024-206688

Published: 2024

Journal Articles

Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Blood (2024) 144 (Supplement 1): 969.

https://doi.org/10.1182/blood-2024-199267

Published: 2024

Journal Articles

Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey

Mikkael A. Sekeres, Sangeetha Venugopal, Namrata S. Chandhok, Justin M. Watts, Terrence Bradley, Justin Taylor, David Sallman, Zhuoer Xie, Eric Padron, Shelby Sullivan, Emily Zyborowicz, Jeffrey Carter, Cherilyn Heggen, Lindsay Gurska, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 3679.

https://doi.org/10.1182/blood-2024-203444

Published: 2024

Journal Articles

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Blood (2023) 142 (Supplement 1): 3228.

https://doi.org/10.1182/blood-2023-189203

Published: 2023

Journal Articles

Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies

Sangeetha Venugopal, Sanam Loghavi, Mark Routbort, Fatima Zahra Jelloul, Rashmi Kanagal-Shamanna, Sherry A. Pierce, Ghayas C. Issa, Hussein A Abbas, Koji Sasaki, Koichi Takahashi, Naval Daver, Farhad Ravandi, Hagop Kantarjian, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 6328–6330.

https://doi.org/10.1182/blood-2022-169778

Published: 2022

Journal Articles

Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents

Sangeetha Venugopal, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Koji Sasaki, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Naval Daver, Farhad Ravandi, Naveen Pemmaraju, Nicholas J. Short, Ghayas C. Issa, Koichi Takahashi, Zeev E. Estrov, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2021) 138 (Supplement 1): 2613.

https://doi.org/10.1182/blood-2021-153475

Published: 2021

Journal Articles

Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia

Sangeetha Venugopal, Nicholas J. Short, Jeffrey L. Jorgensen, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Sherry A. Pierce, Sanam Loghavi, Keyur P. Patel, Ghayas C. Issa, Hagop Kantarjian, Sa A Wang, Farhad Ravandi

Blood (2021) 138 (Supplement 1): 2374.

https://doi.org/10.1182/blood-2021-154105

Published: 2021

Journal Articles

Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML

Sangeetha Venugopal, Tapan M. Kadia, Farhad Ravandi, Courtney D. DiNardo, Naval Daver, Gautam Borthakur, Marina Konopleva, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Abhishek Maiti, Musa Yilmaz, Ghayas C. Issa, Kelly S. Chien, Sherry A. Pierce, Hagop Kantarjian, Nicholas J. Short

Blood (2021) 138 (Supplement 1): 794.

https://doi.org/10.1182/blood-2021-153960

Published: 2021

Journal Articles

A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment‐Naïve High‐Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Sangeetha Venugopal, Hagop Kantarjian, Abhishek Maiti, Nicholas J. Short, Guillermo Montalban-Bravo, Yesid Alvarado, Kelly S. Chien, Rashmi Kanagal-Shamanna, Naveen Pemmaraju, Naval Daver, Tapan M. Kadia, Gautam Borthakur, Elias J. Jabbour, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 245.

https://doi.org/10.1182/blood-2021-153657

Published: 2021

Journal Articles

NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2021) 138 (Supplement 1): 2287.

https://doi.org/10.1182/blood-2021-154059

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Artificial intelligence‑driven virtual tumor board enhances precision care in myelodysplastic syndromes (MDS)

Evaluating large language models in real-world hematologic clinical decision-making: Performance, limitations, and clinical implications

Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study

Preliminary safety and efficacy of the frida study: Iadademstat and gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Results of the Phase 1B study of pegargiminase (ADI-PEG 20) in combination with AZA-VEN in newly diagnosed high-risk AML patients not candidates for intensive chemotherapy

Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus

Azacitidine and venetoclax for HR-MDS: election results pending

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies

Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents

Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia

Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML

A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment‐Naïve High‐Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only